BMRN - CIK 0001048477
BIOMARIN PHARMACEUTICAL INC trades as BMRN and has a market capitalization of $10.86 B, making it the #899 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.22B, up 12.9% from the prior year and net income of $348.90M. This page tracks BIOMARIN PHARMACEUTICAL INC through 2,709 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years BIOMARIN PHARMACEUTICAL INC's revenue grew from $1.12B to $3.22B, a compound annual growth rate of 12.5%. Net profit margin expanded from -56.4% to 10.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-11 |
| Insider sale notice | 144 | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-04 |
| SCHEDULE 13G | - | 2026-04-29 |
| Major company event | 8-K | 2026-04-27 |
| Major company event | 8-K | 2026-04-23 |
_Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at week 52, as well as statistically significant increases in standing height and height Z-score_
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
First Quarter 2026 Total Revenues Increased Year-over-year to $766 million
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
_Acquisition Adds Galafold_ _®_ _(migalastat) for Fabry Disease and Pombiliti_ _®_ _(cipaglucosidase alfa-atga) + Opfolda_ _®_ _(miglustat) for Pompe Disease to BioMarin's Commercial Portfolio_
The largest companies sharing BIOMARIN PHARMACEUTICAL INC's SEC industry classification (pharmaceutical preparations).
BIOMARIN PHARMACEUTICAL INC (BMRN) has a market capitalization of $10.86 B as of 2026-06-10, ranking #899 among US-listed companies.
BIOMARIN PHARMACEUTICAL INC reported revenue of $3.22B for fiscal year 2025, an increase of 12.9% year over year.
Yes. BIOMARIN PHARMACEUTICAL INC reported net income of $348.90M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.